Alivus Life Sciences Ltd Q1 FY27 Earnings Call: Guides 30-32% EBITDA Margin, Non-GPL Grows 26.5%

Alivus Life Sciences Ltd held its Q1 FY27 earnings call on July 30, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue Miss on GPL Drag; Margins Surprise on Mix

• Revenue of Rs.640 Cr — grew 6.4% YoY (segments cite 6.0–6.4%), below the 10–12% full-year guidance run-rate, due to a steep 52.6% YoY decline in the GPL business.
• Gross margin of 60.2% — up 510 bps YoY, driven by new launches, favourable product mix and operational efficiency; management believes ~60% is sustainable near term.
• EBITDA of Rs.234 Cr — margin of 36.6%, up 650 bps YoY, well above the 30–32% full-year guide, aided by the temporary GPL contraction.
• PAT of Rs.160 Cr — margin of 25%; cash and equivalents stood at Rs.880 Cr as of 30 June 2026; company remains debt-free.
• R&D spend of Rs.24 Cr — representing 3.7% of sales in Q1 FY 2026-2027, with a steady-state target of ~4% (period unspecified).

Chronic-Led Portfolio Powers 26.5% Non-GPL Expansion

• Non-GPL business grew 26.5% YoY — currency headwind of ~7% trimmed constant-currency growth to ~20%; volume contributed 21–22%, while price declined 1–2% in Q1 FY 2026-2027.
• GPL business declined 52.6% YoY — attributed to inventory acceleration in Q1 FY 2026-2027; management expects the full year to be flattish, maintaining the Rs.700–750 Cr range seen over the past three years, citing one large customer with >50 commercial products.
• Chronic therapies contributed 74% of Q1 FY 2026-2027 revenue; CVS and CNS together accounted for 58% of the top line, underscoring the high-margin therapeutic mix.
• Non-GPL is more margin-accretive than GPL, management confirmed, so the mix shift toward non-GPL supported the 510 bps gross margin expansion.
• GPL is expected to recover in H2 FY 2026-2027, which will blend EBITDA margins lower toward the guided 30–32% range.

CDMO Run-Rate of ~Rs.165 Cr; 7 New Inquiries in Active Discussion

• CDMO revenue of ~Rs.160–170 Cr (current run rate, Q1 FY 2026-2027) — grew 3.8% YoY in Q1; management expects improvement in H2 FY 2026-2027 as two new projects ramp up and older projects recover.
• 7 new inquiries under active discussion — current revenue is derived from 5 projects; CDMO is expected to grow faster than the overall business over the next two to three years.
• CDMO margin of ~33% in Q1 FY 2026-2027 — management expects margin improvement as CDMO scales and new API launches contribute, sustaining a 33–34% range.
• HPAPI portfolio: 29 products in the active grid, addressing a total addressable market of $82 Bn; new HPAPI launches are expected around the end of calendar 2027 (FY 2027-2028), with no new launches in FY 2026-2027, though buy-launch quantities could generate earlier revenue.
• Management cited that margin growth over Q3–Q4 FY 2025-2026 and Q1 FY 2026-2027 was driven partly by CDMO and partly by new API launches.

EBITDA Guide of 30–32% with Potential Upside; Input Cost Pressures Building

• EBITDA margin guidance for FY 2026-2027: 30–32% — CFO Tushar Mistry guided 32% on a conservative basis, with potential to reach 34% if the steady-state environment holds (i.e., no significant war-like disruption).
• Gross margins of ~60% are considered sustainable near term, with only occasional quarterly variations, driven by launches and operational efficiency.
• Raw material costs rising — solvents and KSMs are seeing price increases; the company is monitoring costs daily and engaging customers for partial pass-throughs, noting that full pass-through is not possible across the board.
• Membrane-based solvent recovery technology introduced — may improve recovery by 5–10% (near-term potential), though complete recovery is not achievable.
• PAT margins expected to remain "good" despite higher R&D spend; investment is focused on new API, next-generation processes, and specialty CDMO projects.

Solapur Delayed ~1 Year; Brownfield Expansions Sufficient for FY27–FY28

• Solapur Phase 2 pushed out ~1 year — management prefers to focus on Phase 1 (operational by early Q3 FY 2026-2027, around Diwali 2026) and Phase 1.1 (Q4 FY 2026-2027) to avoid under-absorption.
• Brownfield expansions on track — Dahej adding 160 KL, Ankleshwar adding ~ 110 KL of capacity; management confirmed this is sufficient to support double-digit growth for both FY 2026-2027 and FY 2027-2028.
• Current facility utilisation at 80–90% — management does not see near-term capacity constraints given the brownfield additions.
• CAPEX of Rs.85 Cr in Q1 FY 2026-2027; full-year CAPEX guidance for FY 2026-2027 stands at Rs.540 Cr.
• Solapur initially for intermediates — it will handle large-volume intermediates for captive consumption, then serve ROW business for ~1 year, as 80%+ of Alivus’s business is regulated-market products that cannot be produced there yet; a backward-integration block is also planned at Solapur.

10–12% Revenue Growth Guided; Regulatory Tailwinds & M&A Optionality

• FY 2026-2027 revenue guidance: 10–12% — management expects steady growth over coming quarters with strong profitability, supported by improving demand trends and operational discipline.
• GPL expected flattish for FY 2026-2027 at Rs.700–750 Cr range; Q1’s steep decline is not seen as an indicator for the full year, based on a large customer with >50 commercial products.
• Regulatory compliance tailwind — received a VAI (Voluntary Action Indicated) at Ankleshwar and an NAI (No Action Indicated) at the Hague, leading to a lighter audit calendar from major agencies in FY 2026-2027.
• M&A optionality — management actively looking for synergistic "API-plus" acquisitions for lateral expansion, with Rs.800 Cr in cash on the balance sheet (segment 12), plus additional short-term investments taking total to Rs.880 Cr.
• Rupee depreciation is a tailwind for net exporters; inventory is being built to support customers at predictable prices; receivables remain timely with no defaults.
• Key risks: raw material cost inflation (solvents, KSMs), war-related disruption, and the ~1-year Solapur delay limiting regulated-market capacity until agency inspection is completed.